Myowomb-M
Myowomb-M combines myoinositol with sustained-release metformin to address insulin resistance and support ovulation induction in women with PCOS, offering a dual-action pharmacological and nutraceutical approach.
Description
Myowomb-M combines myoinositol with sustained-release metformin to address insulin resistance and support ovulation induction in women with PCOS, offering a dual-action pharmacological and nutraceutical approach.
Myowomb-M is a Schedule G bilayered tablet that pairs myoinositol's insulin-sensitizing nutraceutical action with metformin SR's established pharmacological glucose-lowering mechanism. This combination reduces hyperinsulinemia, lowers androgen levels, and restores ovulatory cycles in PCOS. The sustained-release metformin minimizes GI side effects compared to immediate-release formulations. Requires prescription from a registered medical practitioner.
Benefits
- Dual-action: nutraceutical + pharmacological insulin sensitization
- Restores regular ovulatory cycles in PCOS
- Reduces fasting insulin and LH:FSH ratio
- SR Metformin improves tolerability with reduced GI side effects
- Supports weight management in obese PCOS patients
Indications
PCOS with insulin resistance, Anovulatory PCOS requiring pharmacological intervention, Metabolic syndrome associated with PCOS, Adjuvant in ovulation induction protocols, Pre-gestational diabetes risk in PCOS
Product Specifications
| Product Name | Myowomb-M |
|---|---|
| Category | Not assigned |
| Prescription Required | Yes |
| Packaging | 10×10 Tablets (Blister Strip) |
| Featured | No |
Medical Disclaimer
The information on this page is provided for general reference only and should not replace advice from a qualified healthcare professional.
Need Help?
Contact our team for product availability, ordering support, or general inquiries.
Contact Sales Team